We present an 89-year-old woman with newly diagnosed atrial flutter associated with a flare of her rheumatoid arthritis (RA). She had a history of diet-controlled type 2 diabetes mellitus, hypertension, and RA and presented with lightheadedness and worsening hand pain. She was found to be in new atrial flutter with rapid ventricular response and to have an active RA flare. In addition to adequate atrial flutter rate control, her RA flare was managed by adding hydroxychloroquine and doubling her existing methotrexate dose.
A trial fl utter is a common arrhythmia that carries a high burden of morbidity in the elderly population (1). Cardiac-specifi c mechanisms often are implicated in contributing to disease onset, but systemic factors may play an important role in triggering or initiating newly identifi ed cases of atrial fl utter.
CASE DESCRIPTION
An 89-year-old woman with diet-controlled type 2 diabetes mellitus, hypertension, and rheumatoid arthritis (RA) presented with lightheadedness and worsening hand pain. Her initial electrocardiogram revealed atrial fl utter with variable block and a rapid ventricular response (Figure 1 ). Her body mass index was 31.2 kg/m 2 , and her proximal interphalangeal joints were mildly warm and tender bilaterally (Figure 2 ). Her leukocyte count ranged from 10.4 to 14.6 × 10 3 /µL, and her erythrocyte sedimentation rate was 119 mm/h. Chest radiography and urine and blood cultures revealed no source of active infection, and she remained afebrile during the course of the admission. Her echocardiogram showed moderate left atrial dilation, mild right atrial dilation, thickened ventricular walls without wall motion abnormalities, and an ejection fraction of 65%. Her thyroid function testing was within normal limits. She had been admitted with acute kidney injury and mild altered mental status 2 weeks prior to the present admission. Due to concerns for potential medication-related side effects, her RA regimen was changed. Specifi cally, her hydroxychloroquine was discontinued and her methotrexate dose was decreased by half (from 20 to 10 mg/m 2 once weekly). No other medication changes to her home regimen preceded this admission. During the current admission, her rapid ventricular response required high-dose multiagent nodal blockade to achieve adequate control. After several days of dose titration, her heart rate normalized with metoprolol succinate 150 mg twice daily, diltiazem sustained-release 180 mg twice daily, and digoxin 0.125 mg daily. She remained in atrial fl utter throughout hospitalization, and her symptoms quickly resolved with heart rate control. Her RA fl are was managed by reinstating the hydroxychloroquine and doubling the methotrexate dose to 20 mg weekly (her original dose).
DISCUSSION
Approximately 200,000 patients are newly diagnosed with atrial fl utter annually in the United States (1). These estimates are likely higher in elderly patients with comorbid cardiopulmonary disease. In population-based studies, atrial fl utter represents a predictor of late mortality independent of other traditional cardiovascular risk factors (2) .
There is increasing recognition of the systemic infl ammatory profi le of RA and its potent effects on cardiac function. Mechanistically, RA may contribute to conduction disturbances (3) and progressive diastolic dysfunction (4) . To the best of our knowledge, no data are available evaluating the association between RA and atrial fl utter, and particularly RA fl ares and atrial fl utter. Although often approached and managed similarly, atrial fl utter and atrial fi brillation have distinct epidemiological and clinical risk factors (5) . A Danish national cohort study of over 4 million patients in inpatient and outpatient care centers showed that patients with RA were at increased risk for atrial fi brillation and stroke, regardless of age and sex, over a mean follow-up of 4.8 years (6) . A more recent investigation showed an increased rate of hospitalization for atrial fi brillation in RA patients compared with matched controls (7). However, after accounting for relevant baseline covariates, no increased risk of atrial fi brillation was observed Sudden flare of rheumatoid arthritis associated with newly diagnosed atrial flutter Muthiah Vaduganathan, MD, MPH, and Joel N. Auslander, MD in RA patients (7). Our patient had evidence of a concurrent active RA fl are given her exacerbated pain symptoms and elevated infl ammatory markers. She developed atrial fl utter after her RA medications were both discontinued and decreased, likely leading to an RA fl are. Active disease and augmentation of circulating infl ammatory markers may have contributed to her new-onset atrial fl utter (8) .
The implications of a potential relation between RA and atrial fl utter are presently unclear. Routine screening of patients with systemic infl ammatory disorders with electrocardiograms is controversial (9) . Our initial experience raises the question of whether the relation between these clinical entities is coincidental, correlated, or causal. Our patient's medical comorbidities and enlarged biatrial sizes likely increased her baseline risk of experiencing atrial fl utter.
